Patents by Inventor Noriyuki NII

Noriyuki NII has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compound
    Patent number: 11897879
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 13, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • Fused heterocyclic compound
    Patent number: 11390634
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: July 19, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20220089595
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 24, 2022
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20220048916
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: November 27, 2019
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • Heterocyclic compound
    Patent number: 11230545
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: January 25, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20210332045
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • FUSED HETEROCYCLIC COMPOUND
    Publication number: 20210115067
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Application
    Filed: December 22, 2020
    Publication date: April 22, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
  • Fused heterocyclic compound
    Patent number: 10981934
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 20, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
  • FUSED HETEROCYCLIC COMPOUND
    Publication number: 20200140462
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Application
    Filed: October 25, 2019
    Publication date: May 7, 2020
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
  • Fused heterocyclic compound
    Patent number: 10577382
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein].
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 3, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
  • Bicyclic compound
    Patent number: 10301292
    Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 28, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Ryo Mizojiri, Hiroshi Banno, Moriteru Asano, Daisuke Tomita, Noriyuki Nii, Hironobu Maezaki, Michiko Tawada
  • FUSED HETEROCYCLIC COMPOUND
    Publication number: 20190106437
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Application
    Filed: April 27, 2017
    Publication date: April 11, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
  • Monocyclic compound
    Patent number: 10252997
    Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 9, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Moriteru Asano, Daisuke Tomita, Hiroshi Banno, Michiko Tawada, Noriyuki Nii, Krista E. Gipson, Hironobu Maezaki, Shuntarou Tsuchiya, Mayumi Imai, Yuichiro Amano
  • Quinoxaline compounds and uses thereof
    Patent number: 10144742
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 4, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • MONOCYCLIC COMPOUND
    Publication number: 20180079723
    Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.
    Type: Application
    Filed: March 30, 2016
    Publication date: March 22, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Moriteru ASANO, Daisuke TOMITA, Hiroshi BANNO, Michiko TAWADA, Noriyuki NII, Krista E. GIPSON, Hironobu MAEZAKI, Shuntaro TSUCHIYA, Mayumi IMAI, Yuichiro AMANO
  • BICYCLIC COMPOUND
    Publication number: 20180002322
    Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 4, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Hiroshi BANNO, Moriteru ASANO, Daisuke TOMITA, Noriyuki Nii, Hironobu MAEZAKI, Michiko TAWADA
  • QUINOXALINE COMPOUNDS AND USES THEREOF
    Publication number: 20170174704
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Application
    Filed: April 17, 2015
    Publication date: June 22, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • PYRIDAZINE COMPOUND
    Publication number: 20170015654
    Abstract: The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula (where each symbol is as defined as in the Specification) or a salt thereof.
    Type: Application
    Filed: March 11, 2015
    Publication date: January 19, 2017
    Inventors: Keisuke IMAMURA, Naoki TOMITA, Yoshiteru ITO, Koji ONO, Hironobu MAEZAKI, Noriyuki NII